Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Sep 4;2014(9):CD000239.
doi: 10.1002/14651858.CD000239.pub2.

Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients

Helle Krogh Johansen  1 , Peter C Gøtzsche
Affiliations
Meta-Analysis

Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients

Helle Krogh Johansen et al. Cochrane Database Syst Rev. .

Abstract

Background: Systemic fungal infection is considered to be an important cause of morbidity and mortality in cancer patients, particularly those with neutropenia. Antifungal drugs are often given prophylactically, or empirically to patients with persistent fever.

Objectives: To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia.

Search methods: We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified articles.

Selection criteria: Randomised clinical trials comparing fluconazole with amphotericin B.

Data collection and analysis: The two review authors independently assessed trial eligibility and risk of bias, and abstracted data.

Main results: Seventeen trials (3798 patients, 381 deaths) were included. In two large three-armed trials, results for amphotericin B were combined with results for nystatin in a 'polyene' group. Because nystatin is an ineffective drug in these circumstances, this approach creates a bias in favour of fluconazole. Furthermore, most patients were randomised to oral amphotericin B, which is poorly absorbed and poorly documented. There was overlap among the 'polyene' trials but we were unable to obtain any information from the trial authors or from Pfizer, the manufacturer of fluconazole, to clarify these issues. There were no significant differences in effect between fluconazole and amphotericin B, but the confidence intervals were wide. More patients dropped out of the study when they received amphotericin B, but as none of the trials were blinded decisions on premature interruption of therapy could have been biased. Furthermore, amphotericin B was not given under optimal circumstances, with premedication to reduce infusion-related toxicity, slow infusion, and with fluid, potassium and magnesium supplements to prevent nephrotoxicity. The major harms were hepatic impairment and gastrointestinal adverse effects with fluconazole and infusion-related toxicity, renal impairment and gastrointestinal adverse effects with amphotericin B. For the 2011 and 2014 updates no additional trials were identified for inclusion.

Authors' conclusions: Amphotericin B has been disfavoured in several of the trials through their design or analysis, or both. Since intravenous amphotericin B is the only antifungal agent for which an effect on mortality has been shown, and since it is considerably cheaper than fluconazole, it should be the preferred agent.

PubMed Disclaimer

Conflict of interest statement

Helle Krogh Johansen ‐ nothing to declare Peter C Gøtzsche ‐ nothing to declare

Figures

1.1
1.1. Analysis
Comparison 1 Fluconazole versus amphotericin B, Outcome 1 Death.
1.2
1.2. Analysis
Comparison 1 Fluconazole versus amphotericin B, Outcome 2 Death ascribed to fungal infection.
1.3
1.3. Analysis
Comparison 1 Fluconazole versus amphotericin B, Outcome 3 Invasive infections.
1.4
1.4. Analysis
Comparison 1 Fluconazole versus amphotericin B, Outcome 4 Colonisation.
1.5
1.5. Analysis
Comparison 1 Fluconazole versus amphotericin B, Outcome 5 Use of rescue drug.
1.6
1.6. Analysis
Comparison 1 Fluconazole versus amphotericin B, Outcome 6 Dropouts.
1.7
1.7. Analysis
Comparison 1 Fluconazole versus amphotericin B, Outcome 7 Dropouts because of adverse effects.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Akiyama 1993 {published and unpublished data}
    1. Akiyama H, Mori S, Tanikawa S, Sakamaki H, Onozawa Y. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy‐induced neutropenic patients with haematological malignancies. Mycoses 1993;36:373‐8. - PubMed
Anaissie 1996 {published data only}
    1. Anaissie EJ, Darouiche RO, Abi Said D, Uzun O, Mera J, Gentry LO, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clinical Infectious Diseases 1996;23:964‐72. - PubMed
Bodey 1994 {published and unpublished data}
    1. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099‐106. - PubMed
Koh 2002 {published data only}
    1. Koh LP, Kurup A, Goh YT, Fook‐Chong SM, Tan PH. Randomized trial of fluconazole versus low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. American Journal of Hematology 2002;71(4):260‐7. - PubMed
Lake 1996 {published data only}
    1. Lake D, Kunzweiler J. A randomized trial of fluconazole vs. amphotericin B for the treatment of esophageal candidiasis in the adult cancer patient. Proceedings of the Annual Meeting of American Society for Clinical Oncology. 1991:344 (abstract 1222).
    1. Lake DE, Kunzweiler J, Beer M, Buell DN, Islam MZ. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996;42:308‐14. - PubMed
Malik 1998 {published and unpublished data}
    1. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti‐fungal agents in cancer patients with prolonged fever and neutropenia. American Journal of Medicine 1998;105(6):478‐83. - PubMed
Marie 1993 {published and unpublished data}
    1. Lapierre V, Marie J‐P, Pico JL, Molina A, Andremont A, Lagrange P. Intravenous fluconazole (Flu) versus intravenous amphotericin B (AmB) in the management of febrile neutropenic patients: a multicentric randomized study. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, October 1992, Anaheim, California. 1992:214 (abstract 624).
    1. Marie JP, Lapierre V, Pico J, Vekhoff A, Molina L, Andremont A, et al. Etude multicentrique randomisée fluconazole iv versus amphotéricine B iv chez le patient neutropénique et fébrile. Cahiers d'Oncologie 1993;2:171‐3.
    1. Viscoli C. European studies of fluconazole (F) vs amphotericin B (AmB) in febrile neutropenic cancer patients. 7th European Congress of Clinical Microbiology and Infectious Diseases, March 26 to March 30, 1995, Vienna, Austria. 1995:14 (abstract 70).
Menichetti 1994 {published data only}
    1. Menichetti F, Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Annals of Internal Medicine 1994;120:913‐8. - PubMed
Meunier 1991 {published data only}
    1. Meunier F, Aoun M, Janssens M, Dekoster C, Paesmans M. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B. Drug Investigation 1991;3:258‐65.
Ninane 1994 {published data only}
    1. Groll AH, Just‐Nuebling G, Kurz M, et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. Journal of Antimicrobial Chemotherapy 1997;40:855‐62. - PubMed
    1. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. European Journal of Clinical Microbiology and Infectious Diseases 1994;13:330‐7. - PubMed
Philpott‐Howard 1993 {published data only}
    1. Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Haematology and Blood Transfusion 1990;33:546‐50. - PubMed
    1. Finke R. [Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents]. Mycoses 1990;33 Suppl 1:42‐54. - PubMed
    1. Philpott‐Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. Journal of Antimicrobial Chemotherapy 1993;31(6):973‐84. - PubMed
    1. Rozenberg‐Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. Journal of Antimicrobial Chemotherapy 1991;27(3):369‐76. - PubMed
    1. Schuler U, Ehninger G, Brammer K. Oral fluconazole (F) vs oral polyenes (P) as antimycotic prophylaxis in neutropenia: an European multicenter study. Annals of Hematology 1992;65:A120, abstract 356.
Powles 1990 {published data only}
    1. Milliken S, Gore M, Powles R, Harding M, Jameson B, Talbot D, et al. Fluconazole versus polyenes as oral anti‐fungal prophylaxis in autologous and allogeneic bone marrow recipients. Bone Marrow Transplantation 1989;4 Suppl 2:27 (abstract).
    1. Powles RL, Smith C, Treleaven J, Tiley C, Helenglass G. Antifungal prophylaxis with fluconazole in bone marrow transplants. Bone Marrow Transplantation 1990;5 Suppl 2:135, abstract 291.
Silling 1999 {published data only}
    1. Silling G, Fegeler W, Roos N, Essink M, Büchner T. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 1999;42 Suppl 2:101‐4. - PubMed
    1. Silling G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/5‐fluorocytosine. Mycoses 1999;42(3):159. - PubMed
    1. Silling G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T. Early empiric antifungal therapy of infections in neutropenic patients with hematologic malignancies: fluconazole vs ampho B/5‐FC. Annals of Hematology 1999;78 Suppl 1:S2, abstract 8.
    1. Silling G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T. Fluconazole (FCA) versus amphotericin B/5‐flucytosine (ABF) for the treatment of febrile neutropenia. Annals of Hematology 1995;70 Suppl 1:A101, abstract 28.
    1. Silling‐Engelhardt G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T. Early empiric antifungal treatment of infections in neutropenic patients comparing fluconazole with amphotericin B/5‐flucytosine. Blood 1994;10 Suppl 1:306a.
Teshima 1994 {published and unpublished data}
    1. Teshima H, Masaoka T, Hiraoka A, Miyazaki T, Imarmura M, Kitabayashi A. A randomised study to compare oral fluconazole with oral amphotericin B for suppression of fungal flora and prevention of fungal infection in bone marrow transplantation recipients. Drug Evaluation (Konnichi No Ishoku) 1994;7:535‐42.
Viscoli 1996 {published and unpublished data}
    1. Viscoli C, Castagnola E, Lint MT, Moroni C, Garaventa A, Rossi MR, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. European Journal of Cancer 1996;32A(5):814‐20. - PubMed
Winston 2000 {published and unpublished data}
    1. Winston DJ, Hathorn J, Schuster M. Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomised multicenter trial. 20th International Congress of Chemotherapy, June 29 to July 3, 1997, Sydney, Australia. 1997:87 (abstract 3243).
    1. Winston DJ, Hathorn J, Schuster M. Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomized multi‐center trial. 10th International Symposium on Infections in the Immunocomprised Host, June 21‐24, 1998, Davos, Switzerland. 1998:abstract no 112.
    1. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. American Journal of Medicine 2000;108:282‐9. - PubMed
Wolff 2000 {published data only}
    1. Wolff SN, Fay J, Stevens D, Herzig RH, Pohlman B, Bolwell B, et al. Fluconazole vs low‐dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplantation 2000;25(8):853‐9. - PubMed

References to studies excluded from this review

Ellis 1995 {published data only}
    1. Ellis ME, Halim MA, Spence D, Ernst P, Clink H, Kalin M, et al. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever ‐ preliminary observations from a pilot, exploratory study. Journal of Infection 1995;30:141‐6. - PubMed
Reed 1993 {published data only}
    1. Reed E, Rasmussen J, Roberson P, Armitage J, Bierman P, Vose J, et al. Interim analysis of fluconazole (flu), intermittent amphotericin (ampho) and no treatment (ntx) for prophylaxis of fungal disease in bone marrow transplant (BMT) and acute leukemia (AL) patients (pts). Proceedings of the Annual Meeting of American Society for Clinical Oncology. 1993:465 (abstract A1622).
Timmers 2000 {published data only}
    1. Timmers GJ, Zweegman S, Simoons Smit AM, Loenen AC, Touw D, Huijgens PC. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplantation 2000;25(8):879‐84. - PubMed

Additional references

Bodey 1974
    1. Bodey GP, Rosenbaum B. Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine 1974;53:209‐28. - PubMed
Bow 1997
    1. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Ioannou S. Antifungal prophylaxis in neutropenic cancer patients ‐ a meta‐analysis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28 to October 1, 1997, Toronto, Ontario, Canada. 1997:abstract no LM‐88.
Bow 2002
    1. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized‐controlled clinical trials. Cancer 2002;94:3230‐46. - PubMed
Due 2006
    1. Due AK, Johansen HK, Gøtzsche PC. Fungal infection‐related mortality versus total mortality as an outcome in trials of antifungal agents. BioMed Central Medical Research Methodology 2006;6:40. - PMC - PubMed
Ellis 1992
    1. Ellis ME, al‐Hokail AA, Clink HM, Padmos MA, Ernst P, Spence DG, et al. Double‐blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrobial Agents and Chemotherapy 1992;36:172‐9. - PMC - PubMed
Eriksson 2001
    1. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322(7286):579‐82. - PMC - PubMed
Goodman 1992
    1. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 1992;326(13):845‐51. - PubMed
Groll 1997
    1. Groll AH, Just‐Nuebling G, Kurz M, Mueller C, Nowak‐Goettl U, Schwabe D, et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. The Journal of Antimicrobial Chemotherapy 1997;40:855‐62. - PubMed
Gøtzsche 1997
    1. Gøtzsche PC, Johansen HK. Meta‐analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997;314:1238‐44. - PMC - PubMed
Gøtzsche 2002a
    1. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000026] - DOI - PubMed
Gøtzsche 2002b
    1. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002033] - DOI - PubMed
Hemminki 1980
    1. Hemminki E. Study of information submitted by drug companies to licensing authorities. BMJ 1980;280(6217):833‐6. - PMC - PubMed
Johansen 1997
    1. Johansen HK, Gøtzsche PC. Systematic reviews of prophylactic or empirical antifungal therapy in cancer patients with neutropenia. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28 to October 1, 1997, Toronto, Ontario, Canada. 1997:abstract no LM‐89.
Mayer 1999
    1. Mayer J, Doubek M, Vorlicek J. Must we really fear toxicity of conventional amphotericin B in oncological patients?. Support Care Cancer 1999;7(1):51‐5. - PubMed
Nakielny 1993
    1. Nakielny J. Effective and acceptable treatment for depression (letter). BMJ 1993;306:1125. - PMC - PubMed
Nath 1999
    1. Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrobial Agents and Chemotherapy 1999;43(6):1417‐23. - PMC - PubMed
Slavin 1995
    1. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation ‐ a prospective, randomized, double‐blind study. Journal of Infectious Diseases 1995;171(6):1545‐52. - PubMed
Smith 1998
    1. Smith GD, Egger M. Unresolved issues and future developments. BMJ 1998;316:221‐5. - PMC - PubMed
Song 1993
    1. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al. Selective serotonin reuptake inhibitors: meta‐analysis of efficacy and acceptability. BMJ 1993;306:683‐7. - PMC - PubMed
Stern 1997
    1. Stern JM, Simes JR. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640‐5. - PMC - PubMed
Verfaillie 1991
    1. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991;8:177‐84. - PubMed
Viscoli 1994
    1. Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. European Journal of Cancer 1994;30A:430‐7. - PubMed
Working Party 1995
    1. Working Party of the British Society for Antimicrobial Chemotherapy. Antifungal drug chemotherapy. Antifungal drug susceptibility testing. Journal of Antimicrobial Chemotherapy 1995;36:899‐909. - PubMed

References to other published versions of this review

Johansen 1999
    1. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta‐analysis. JAMA 1999;282:1752‐9. - PubMed
Johansen 2000
    1. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD000239] - DOI - PubMed
Johansen 2002
    1. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000239] - DOI - PubMed

MeSH terms

LinkOut - more resources